Samsung Biologics: Samsung Biologics Q1 Net Soars on Expanded Output, Weak Won

SEOUL, April 23 (Korea Bizwire) - Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, said Wednesday its first-quarter net profit more than doubled from a year earlier, driven by expanded production and a weaker won. Net profit for the three months ended March surged to 375.6 billion won (US$263.9 million), up from [...]The post Samsung Biologics Q1 Net Soars on Expanded Output, Weak Won appeared first on Be Korea-savvy.